A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2017
Price : $35 *
At a glance
- Drugs Leuprorelin (Primary) ; Orteronel (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms NEPTUNE
- 31 Aug 2018 Biomarkers information updated
- 02 Sep 2015 Accrual to date is 11% according to United Kingdom Clinical Research Network record.
- 11 Jul 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.